Cargando…

Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides

Apurinic/apyrimidinic endonuclease (APE) is a key enzyme involved in DNA base excision repair (BER) that is often expressed at elevated levels in human cancers. Pancreatic cancer cells treated with the nucleoside analogue gemcitabine (2′, 2′-difluoro-2′deoxycytidine) showed increases in APE/redox ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lau, J P, Weatherdon, K L, Skalski, V, Hedley, D W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747714/ https://www.ncbi.nlm.nih.gov/pubmed/15316562 http://dx.doi.org/10.1038/sj.bjc.6602080

Ejemplares similares

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells
por: Wacheck, V, et al.
Publicado: (2003)

Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor
por: Shi, W, et al.
Publicado: (2002)

Analysis of nuclear transport signals in the human apurinic/apyrimidinic endonuclease (APE1/Ref1)
por: Jackson, Elias B., et al.
Publicado: (2005)

Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers
por: Al-Attar, A, et al.
Publicado: (2010)

Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage
por: Zaky, Amira, et al.
Publicado: (2008)

Dual Regulatory Roles of Human AP-Endonuclease (APE1/Ref-1) in CDKN1A/p21 Expression
por: Sengupta, Shiladitya, et al.
Publicado: (2013)

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy
por: Atkins, H, et al.
Publicado: (2003)

Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein
por: Choi, Sunga, et al.
Publicado: (2016)

APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease
por: Sahakian, Lauren, et al.
Publicado: (2023)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1–STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival
por: Cardoso, Angelo A., et al.
Publicado: (2012)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Co‐delivery of microRNA‐21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy
por: Li, Yaqing, et al.
Publicado: (2017)

Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
por: Choi, Sunga, et al.
Publicado: (2016)

Polymerase-Endonuclease Amplification Reaction (PEAR) for Large-Scale Enzymatic Production of Antisense Oligonucleotides
por: Wang, Xiaolong, et al.
Publicado: (2010)

Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers.
por: Herring, C. J., et al.
Publicado: (1998)

Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines
por: Sekhon, J, et al.
Publicado: (2002)

APE1/Ref-1 Role in Inflammation and Immune Response
por: Oliveira, Thais Teixeira, et al.
Publicado: (2022)

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
por: Sangar, V K, et al.
Publicado: (2004)

Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity
por: Hosoi, Y, et al.
Publicado: (2002)

Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study
por: Jo, Yumin, et al.
Publicado: (2021)

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C
por: Whitehouse, P A, et al.
Publicado: (2003)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
por: Le, Bao T., et al.
Publicado: (2018)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression
por: YANG, ZHEN, et al.
Publicado: (2014)

Elevation of Serum APE1/Ref-1 in Experimental Murine Myocarditis
por: Jin, Seon-Ah, et al.
Publicado: (2017)

APE1/Ref-1 as a Novel Target for Retinal Diseases
por: Heisel, Curtis, et al.
Publicado: (2021)

A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
por: Simonenko, Vera, et al.
Publicado: (2020)

Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor
por: Qian, Chengyuan, et al.
Publicado: (2014)

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis
por: Lun, Shichun, et al.
Publicado: (2019)

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
por: Bergman, A M, et al.
Publicado: (2003)

Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1
por: Eberle, J, et al.
Publicado: (2002)

Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length
por: Tian, X-X, et al.
Publicado: (2002)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Targeted delivery of antisense oligonucleotides to pancreatic β-cells
por: Ämmälä, C., et al.
Publicado: (2018)

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer
por: Shin, Ju Hyun, et al.
Publicado: (2015)

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma
por: Alhazmi, Razan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9pqektbod10i7cluhnk4elhrt5